Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 54, Issue 1, 2015, Pages 25-36

  Jensen, Karsten Gjessing ^a   Juul, Klaus ^b   Fink Jensen, Anders ^c   Correll, Christoph U ^d   Pagsberg, Anne Katrine ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

adolescents; antipsychotics; children; ECG; QTc

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ELECTROCARDIOGRAPHY; HUMAN; LONG QT SYNDROME; META ANALYSIS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME;

EID: 85003042936     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2014.10.002     Document Type: Review

References (93)

1. Olfson, M., Blanco, C., Liu, S.M., Wang, S., Correll, C.U., National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69 (2012), 1247–1256.
2. Panagiotopoulos, C., Ronsley, R., Elbe, D., Davidson, J., Smith, D.H., First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 19 (2010), 124–137.
3. Vitiello, B., Correll, C., van Zwieten-Boot, B., Zuddas, A., Parellada, M., Arango, C., Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19 (2009), 629–635.
4. Haddad, P.M., Anderson, I.M., Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62 (2002), 1649–1671.
5. Nielsen, J., Graff, C., Kanters, J.K., Toft, E., Taylor, D., Meyer, J.M., Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 25 (2011), 473–490.
6. Benatar, A., Decraene, T., Comparison of formulae for heart rate correction of QT interval in exercise ECGs from healthy children. Heart 86 (2001), 199–202.
7. Desai, M., Li, L., Desta, Z., Malik, M., Flockhart, D., Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 55 (2003), 511–517.
8. Bazett, H.C., An analysis of the time-relations of electrocardiograms. Heart 7 (1920), 353–370.
9. Fridericia, L.S., The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 8 (2003), 343–351.
10. Ponte, M.L., Keller, G.A., Di, G.G., Mechanisms of drug induced QT interval prolongation. Curr Drug Saf 5 (2010), 44–53.
11. Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M., Malhotra, A.K., Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302 (2009), 1765–1773.
12. Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey, D.E., Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 (2005), 1115–1121.
13. Meyer, J., Koro, C.E., L'Italien, G.J., The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 17 (2005), 173–180.
14. Raedler, T.J., Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 23 (2010), 574–581.
15. Al-Khatib, S.M., LaPointe, N.M., Kramer, J.M., Califf, R.M., What clinicians should know about the QT interval. JAMA 289 (2003), 2120–2127.
16. Alvarez, P.A., Pahissa, J., QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 5 (2010), 97–104.
17. Zumhagen, S., Stallmeyer, B., Friedrich, C., Eckardt, L., Seebohm, G., Schulze-Bahr, E., Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy. Herzschrittmacherther Elektrophysiol 23 (2012), 211–219.
18. Beach, S.R., Celano, C.M., Noseworthy, P.A., Januzzi, J.L., Huffman, J.C., QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54 (2013), 1–13.
19. Blair, J., Taggart, B., Martin, A., Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. J Neural Transm 111 (2004), 791–815.
20. Francis, P.D., Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr 14 (2002), 224–230.
21. McNally, P., McNicholas, F., Oslizlok, P., The QT interval and psychotropic medications in children: recommendations for clinicians. Eur Child Adolesc Psychiatry 16 (2007), 33–47.
22. Kendall, T., Hollis, C., Stafford, M., Taylor, C., Guideline Development Group. Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ, 346, 2013, f150.
23. McClellan, J., Stock, S., American Academy of Child and Adolescent Psychiatry Committee on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 52 (2013), 976–990.
24. Stigler, K.A., Diener, J.T., Kohn, A.E., et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19 (2009), 265–274.
25. Ho, J.G., Caldwell, R.L., McDougle, C.J., et al. The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 22 (2012), 277–283.
26. Kent, J.M., Kushner, S., Ning, X., et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 43 (2013), 1773–1783.
27. Haas, M., Unis, A.S., Armenteros, J., Copenhaver, M.D., Quiroz, J.A., Kushner, S.F., A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19 (2009), 611–621.
28. Haas, M., Delbello, M.P., Pandina, G., et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 11 (2009), 687–700.
29. Haas, M., Eerdekens, M., Kushner, S., et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 194 (2009), 158–164.
30. Reyes, M., Croonenberghs, J., Augustyns, I., Eerdekens, M., Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16 (2006), 260–272.
31. Reyes, M., Olah, R., Csaba, K., Augustyns, I., Eerdekens, M., Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 15 (2006), 97–104.
32. Croonenberghs, J., Fegert, J.M., Findling, R.L., De Smedt, G., Van Dongen, S., Risperidone Disruptive Behavior Study Group. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44 (2005), 64–72.
33. Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., Eerdekens, M., A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163 (2006), 402–410.
34. Snyder, R., Turgay, A., Aman, M., et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41 (2002), 1026–1036.
35. Turgay, A., Binder, C., Snyder, R., Fisman, S., Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110, 2002, e34.
36. Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., Findling, R.L., Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159 (2002), 1337–1346.
37. Shea, S., Turgay, A., Carroll, A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004), e634–e641.
38. Findling, R.L., Kauffman, R.E., Sallee, F.R., et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 28 (2008), 441–446.
39. Findling, R.L., Correll, C.U., Nyilas, M., et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 15 (2013), 138–149.
40. Findling, R.L., Kauffman, R., Sallee, F.R., et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 19 (2009), 431–439.
41. Kryzhanovskaya, L., Schulz, S.C., McDougle, C., et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48 (2009), 60–70.
42. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Updated March 2011. Available at: www.cochrane-handbook.org. Accessed June 15, 2014.
43. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
44. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
45. Biederman, J., Mick, E., Spencer, T., Dougherty, M., Aleardi, M., Wozniak, J., A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord 9 (2007), 888–894.
46. Biederman, J., Mick, E., Spencer, T., et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 12 (2007), 683–689.
47. Blair, J., Scahill, L., State, M., Martin, A., Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44 (2005), 73–79.
48. Buitelaar, J.K., van der Gaag, R.J., Cohen-Kettenis, P., Melman, C.T., A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62 (2001), 239–248.
49. Correll, C.U., QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry 72 (2011), 854–860.
50. Cui, Y.H., Zheng, Y., Yang, Y.P., Liu, J., Li, J., Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China. J Child Adolesc Psychopharmacol 20 (2010), 291–298.
51. DelBello, M.P., Versavel, M., Ice, K., Keller, D., Miceli, J., Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 18 (2008), 491–499.
52. DelBello, M.P., Adler, C.M., Whitsel, R.M., Stanford, K.E., Strakowski, S.M., A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 68 (2007), 789–795.
53. Delbello, M.P., Schwiers, M.L., Rosenberg, H.L., Strakowski, S.M., A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41 (2002), 1216–1223.
54. Desousa, A., An open-label trial of risperidone and fluoxetine in children with autistic disorder. Indian J Psychol Med 32 (2010), 17–21.
55. Findling, R.L., Pathak, S., Earley, W.R., Liu, S., DelBello, M., Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. J Child Adolesc Psychopharmacol 23 (2013), 490–501.
56. Findling, R.L., Johnson, J.L., McClellan, J., et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49 (2010), 583–594 quiz 632.
57. Findling, R.L., Robb, A., Nyilas, M., et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165 (2008), 1432–1441.
58. Geller, B., Luby, J.L., Joshi, P., et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 69 (2012), 515–528.
59. Gulisano, M., Cali, P.V., Cavanna, A.E., Eddy, C., Rickards, H., Rizzo, R., Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 32 (2011), 1213–1217.
60. Hagman, J., Gralla, J., Sigel, E., et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry 50 (2011), 915–924.
61. Joshi, G., Petty, C., Wozniak, J., et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology 227 (2013), 449–458.
62. Joshi, G., Petty, C., Wozniak, J., et al. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord 136 (2012), 1143–1153.
63. Kronenberger, W.G., Giauque, A.L., Lafata, D.E., Bohnstedt, B.N., Maxey, L.E., Dunn, D.W., Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol 17 (2007), 334–347.
64. Lyon, G.J., Samar, S., Jummani, R., et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol 19 (2009), 623–633.
65. Malone, R.P., Delaney, M.A., Hyman, S.B., Cater, J.R., Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17 (2007), 779–790.
66. Marcus, R.N., Owen, R., Kamen, L., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48 (2009), 1110–1119.
67. Margari, L., Matera, E., Craig, F., et al. Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol 28 (2013), 177–183.
68. Murphy, T.K., Mutch, P.J., Reid, J.M., et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmaco 19 (2009), 441–447.
69. Owen, R., Sikich, L., Marcus, R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124 (2009), 1533–1540.
70. Pandina, G., Kushner, S., Karcher, K., Haas, M., An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child Adolesc Psychiatry Ment Health, 6, 2012, 23.
71. Sallee, F.R., Miceli, J.J., Tensfeldt, T., Robarge, L., Wilner, K., Patel, N.C., Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry 45 (2006), 720–728.
72. Sikich, L., Frazier, J.A., McClellan, J., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry 165 (2008), 1420–1431.
73. Tohen, M., Kryzhanovskaya, L., Carlson, G., et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164 (2007), 1547–1556.
74. Sikich, L., Hamer, R.M., Bashford, R.A., Sheitman, B.B., Lieberman, J.A., A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29 (2004), 133–145.
75. Singh, J., Robb, A., Vijapurkar, U., Nuamah, I., Hough, D., A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70 (2011), 1179–1187.
76. Kuperman, S., Calarge, C., Kolar, A., Holman, T., Barnett, M., Perry, P., An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Ann Clin Psychiatry 23 (2011), 270–276.
77. Stocks, J.D., Taneja, B.K., Baroldi, P., Findling, R.L., A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol 22 (2012), 102–111.
78. Germano, E., Italiano, D., Lamberti, M., et al. ECG parameters in children and adolescents treated with aripiprazole and risperidone. Prog Neuropsychopharmacol Biol Psychiatry 51 (2014), 23–27.
79. Findling, R.L., Cavus, I., Pappadopulos, E., et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 23 (2013), 531–544.
80. Findling, R.L., Cavus, I., Pappadopulos, E., et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 23 (2013), 545–557.
81. Haas, M., Karcher, K., Pandina, G.J., Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol 18 (2008), 337–345.
82. Stigler, K.A., Mullett, J.E., Erickson, C.A., Posey, D.J., McDougle, C.J., Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl) 223 (2012), 237–245.
83. Leucht, S., Cipriani, A., Spineli, L., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
84. Wenzel-Seifert, K., Wittmann, M., Haen, E., QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 108 (2011), 687–693.
85. De Hert, M., Detraux, J., van Winkel, R., Yu, W., Correll, C.U., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8 (2012), 114–126.
86. Camm, A.J., Karayal, O.N., Meltzer, H., et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs 26 (2012), 351–365.
87. Strom, B.L., Eng, S.M., Faich, G., et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 168 (2011), 193–201.
88. Marder, S.R., McQuade, R.D., Stock, E., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61 (2003), 123–136.
89. Lexchin, J., Sponsorship bias in clinical research. Int J Risk Saf Med 24 (2012), 233–242.
90. Chugh, S.S., Reinier, K., Balaji, S., et al. Population-based analysis of sudden death in children: the Oregon Sudden Unexpected Death Study. Heart Rhythm 6 (2009), 1618–1622.
91. Laursen, T.M., Munk-Olsen, T., Gasse, C., Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One, 6, 2011, e24597.
92. Galli-Tsinopoulou, A., Chatzidimitriou, A., Kyrgios, I., Rousso, I., Varlamis, G., Karavanaki, K., Children and adolescents with type 1 diabetes mellitus have a sixfold greater risk for prolonged QTc interval. J Pediatr Endocrinol Metab 27 (2014), 237–243.
93. Hasnain, M., Vieweg, W.V., QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review. CNS Drugs 28:10 (2014 Oct), 887–920.